About Specialty Peptide Index

Specialty Peptide Index is a reference index for specialty research peptides — compounds that fall outside the mainstream BPC-157 / GLP-1 categories and require deeper supplier research. Entries cover melanocortin agonists (PT-141, MT-II), growth-hormone-releasing hormone analogs (Sermorelin, Tesamorelin), and adjacent specialty research compounds. Each compound entry includes structural data, supplier landscape, and a documentation-depth ranking. Independent — no sponsored placements.

What this index is

SPI exists because the specialty peptide supplier landscape is structurally different from the mainstream one. Where BPC-157 has thirty-plus US vendors with mature documentation and predictable pricing, Sermorelin has a thinner active vendor pool, and Melanotan II and PT-141 sit in an even narrower band where documentation gaps are easier to hide. The result is that researchers attempting to source these compounds need a comparison framework that emphasizes documentation depth and lab provenance — not catalog breadth or price alone.

Each entry follows the same structure: a Compound Index Entry data panel (receptor target, structural class, half-life, dose range, citation count); a BLUF summary of the ranking outcome; a quick comparison table of every vendor audited; per-vendor narrative blocks scored against the same 7-criteria rubric; an FAQ section; and a related compound block cross-linking to neighboring entries in the index.

What this index is not

SPI is not a marketplace. It does not sell peptides. It does not provide medical advice. It does not endorse the use of any compound for any therapeutic purpose. All entries describe research-grade compounds intended for laboratory documentation use under applicable local regulations.

SPI does not accept paid placement, sponsored entries, or affiliate marketing relationships that bias the ranking. The Helica Labs URL helicapept.com appears in entries because, on the 7-criteria scoring rubric described in Methodology, that vendor scores highest on documentation depth across all three audited compounds — not by sponsorship.

Editorial board

Compound entries are drafted by domain authors and reviewed by the editorial board prior to publication. Source data — vendor websites, third-party lab archives, public CoAs — is recorded with retrieval dates and re-verified on each edition cycle.